Trial Profile

A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neratinib (Primary) ; Trastuzumab emtansine
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Apr 2024 Results of molecular markers and mechanisms of resistance , published in the Breast Cancer Research
10 Jan 2023 Status changed from active, no longer recruiting to completed.
07 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com